See more : Sydinv HøjrenteLa MixESG A DKK (SYIHRLMESGADKK.CO) Income Statement Analysis – Financial Results
Complete financial analysis of Guided Therapeutics, Inc. (GTHP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Guided Therapeutics, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Softlab S.p.A. (SOF.MI) Income Statement Analysis – Financial Results
- Arendals Fossekompani ASA (AFK.OL) Income Statement Analysis – Financial Results
- SGT German Private Equity GmbH & Co. KGaA (SGF.DE) Income Statement Analysis – Financial Results
- Cue Health Inc. (HLTHQ) Income Statement Analysis – Financial Results
- Lekoil Limited (LEKOF) Income Statement Analysis – Financial Results
Guided Therapeutics, Inc. (GTHP)
About Guided Therapeutics, Inc.
Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 98.00K | 13.00K | 81.00K | 102.00K | 36.00K | 57.00K | 244.00K | 605.00K | 606.00K | 823.00K | 1.18M | 3.41M | 3.60M | 3.36M | 1.55M | 1.32M | 1.04M | 977.00K | 983.00K | 1.07M | 1.59M | 3.80M | 2.46M | 4.97M | 3.30M | 1.40M | 900.00K | 500.00K | 1.18M | 120.00K | 0.00 |
| Cost of Revenue | 62.00K | 81.00K | 61.00K | 41.00K | 70.00K | 89.00K | 530.00K | 493.00K | 537.00K | 891.00K | 611.00K | 117.00K | 81.00K | 0.00 | 0.00 | 0.00 | 52.00K | 1.01M | 1.43M | 1.11M | 1.06M | 1.62M | 2.06M | 1.27M | 1.30M | 1.20M | -400.00K | -300.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 36.00K | -68.00K | 20.00K | 61.00K | -34.00K | -32.00K | -286.00K | 112.00K | 69.00K | -68.00K | 568.00K | 3.29M | 3.52M | 3.36M | 1.55M | 1.32M | 985.00K | -34.00K | -443.00K | -36.00K | 524.00K | 2.17M | 394.00K | 3.69M | 2.00M | 200.00K | 1.30M | 800.00K | 1.18M | 120.00K | 0.00 |
| Gross Profit Ratio | 36.73% | -523.08% | 24.69% | 59.80% | -94.44% | -56.14% | -117.21% | 18.51% | 11.39% | -8.26% | 48.18% | 96.57% | 97.75% | 100.00% | 100.00% | 100.00% | 94.99% | -3.48% | -45.07% | -3.36% | 33.04% | 57.24% | 16.03% | 74.36% | 60.61% | 14.29% | 144.44% | 160.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 228.00K | 77.00K | 69.00K | 143.00K | 122.00K | 244.00K | 334.00K | 733.00K | 1.48M | 2.79M | 2.74M | 3.23M | 2.78M | 1.81M | 1.41M | 2.06M | 1.93M | 1.96M | 2.03M | 3.62M | 4.11M | 5.83M | 3.84M | 5.80M | 5.20M | 4.20M | 3.40M | 1.80M | 1.19M | 870.00K | 640.00K |
| General & Administrative | 3.00M | 3.01M | 2.17M | 913.00K | 694.00K | 1.08M | 2.26M | 2.81M | 4.10M | 4.65M | 3.53M | 3.92M | 7.21M | 3.05M | 1.94M | 2.28M | 2.46M | 0.00 | 0.00 | 1.87M | 2.15M | 2.79M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 780.00K | 480.00K | 600.00K |
| Selling & Marketing | 268.00K | 181.00K | 141.00K | 139.00K | 87.00K | 195.00K | 245.00K | 393.00K | 718.00K | 1.16M | 901.00K | 424.00K | 287.00K | 131.00K | 63.00K | 42.00K | 217.00K | 0.00 | 0.00 | 679.00K | 735.00K | 1.65M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.27M | 3.19M | 2.31M | 1.05M | 781.00K | 1.27M | 2.50M | 3.20M | 4.82M | 5.81M | 4.43M | 4.35M | 7.49M | 3.18M | 2.00M | 2.32M | 2.46M | 2.45M | 1.99M | 2.54M | 2.89M | 4.43M | 3.79M | 4.13M | 3.10M | 3.00M | 3.40M | 1.70M | 780.00K | 480.00K | 600.00K |
| Other Expenses | 0.00 | 16.00K | 507.00K | 271.00K | 48.00K | 54.00K | 18.00K | 68.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.57M | 3.21M | 0.00 | 0.00 | 0.00 | 458.00K | 400.00K | 500.00K | 400.00K | 300.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 3.49M | 3.27M | 2.38M | 1.20M | 903.00K | 1.52M | 2.84M | 3.93M | 6.30M | 8.60M | 7.17M | 7.57M | 10.27M | 4.99M | 3.41M | 4.38M | 4.39M | 4.41M | 1.45M | 9.37M | 6.99M | 10.26M | 7.63M | 10.40M | 8.70M | 7.70M | 7.20M | 3.80M | 1.97M | 1.35M | 1.24M |
| Cost & Expenses | 3.56M | 3.35M | 2.44M | 1.15M | 973.00K | 1.61M | 3.37M | 4.43M | 6.83M | 9.49M | 7.79M | 7.69M | 10.35M | 4.99M | 3.41M | 4.38M | 4.44M | 5.42M | 2.88M | 10.48M | 8.06M | 11.89M | 9.69M | 11.67M | 10.00M | 8.90M | 6.80M | 3.50M | 1.97M | 1.35M | 1.24M |
| Interest Income | 6.00K | 582.00K | 1.15M | 1.06M | 1.41M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 91.00K | 254.00K | 334.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 278.00K | 582.00K | 1.15M | 1.06M | 1.41M | 1.76M | 1.11M | 1.90M | 1.32M | 979.00K | 45.00K | 72.00K | 80.00K | 1.23M | 3.98M | 1.89M | 1.21M | 709.00K | 177.00K | 920.00K | 328.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 100.00K | -10.00K | -140.00K | 0.00 |
| Depreciation & Amortization | 85.00K | 72.00K | 1.00K | 21.00K | 21.00K | 27.00K | 213.00K | 1.22M | 1.05M | 483.00K | 461.00K | 361.00K | 34.00K | 7.00K | 7.00K | 7.00K | 9.00K | 49.00K | 114.00K | 479.00K | 556.00K | 587.00K | 360.00K | 458.00K | 400.00K | 500.00K | 400.00K | 300.00K | 110.00K | 80.00K | 20.00K |
| EBITDA | -3.13M | -3.69M | -919.00K | 777.00K | -488.00K | 2.81M | -9.38M | -852.00K | -4.53M | -8.42M | -6.71M | -3.92M | -6.53M | -1.61M | -2.22M | -2.91M | 2.45M | -4.59M | -1.82M | -8.93M | -5.91M | -7.50M | -6.88M | -6.24M | -6.30M | -7.00M | -5.50M | -2.70M | -580.00K | -1.41M | -1.22M |
| EBITDA Ratio | -3,189.80% | -24,961.54% | -2,187.65% | -765.69% | -2,411.11% | -2,573.68% | -1,184.43% | -418.02% | -1,027.56% | -1,053.34% | -521.20% | -114.96% | -186.88% | -48.04% | -119.55% | -232.35% | -327.19% | -469.81% | -442.32% | -634.58% | -636.76% | -184.07% | -280.31% | -126.11% | -190.91% | -557.14% | -633.33% | -560.00% | -49.15% | -1,175.00% | 0.00% |
| Operating Income | -3.46M | -3.33M | -2.36M | -1.05M | -937.00K | -1.55M | -3.12M | -3.82M | -6.23M | -8.67M | -6.61M | -4.28M | -6.76M | -1.62M | -1.86M | -3.07M | 2.41M | -4.44M | -1.89M | -9.41M | -6.47M | -8.09M | -7.24M | -6.70M | -6.70M | -7.50M | -5.90M | -3.00M | -790.00K | -1.22M | -1.24M |
| Operating Income Ratio | -3,527.55% | -25,638.46% | -2,916.05% | -1,031.37% | -2,602.78% | -2,715.79% | -1,279.10% | -631.40% | -1,027.56% | -1,053.34% | -560.31% | -125.54% | -187.82% | -48.19% | -120.00% | -232.88% | 232.79% | -454.35% | -192.57% | -876.89% | -407.88% | -212.93% | -294.34% | -134.90% | -203.03% | -535.71% | -655.56% | -600.00% | -66.95% | -1,016.67% | 0.00% |
| Total Other Income/Expenses | -32.00K | -1.01M | 292.00K | 773.00K | -984.00K | 2.56M | -7.58M | -150.00K | -675.00K | -1.21M | -609.00K | -72.00K | 112.00K | -1.23M | -4.35M | -1.74M | 4.63M | 200.00K | -306.00K | 170.00K | 3.86M | -418.00K | 15.00K | 21.00K | 0.00 | 800.00K | 200.00K | 100.00K | 110.00K | -130.00K | 20.00K |
| Income Before Tax | -3.49M | -4.34M | -2.07M | -279.00K | -1.92M | 1.02M | -10.70M | -3.97M | -6.90M | -9.88M | -7.22M | -4.35M | -6.64M | -2.85M | -6.21M | -4.81M | 1.23M | -4.24M | -2.78M | -9.24M | -2.61M | -8.51M | -7.22M | -6.68M | 0.00 | -6.70M | -5.70M | -2.90M | -680.00K | -1.35M | -1.22M |
| Income Before Tax Ratio | -3,560.20% | -33,392.31% | -2,555.56% | -273.53% | -5,336.11% | 1,782.46% | -4,383.61% | -656.20% | -1,138.94% | -1,200.85% | -611.96% | -127.65% | -184.71% | -84.60% | -400.77% | -365.22% | 118.13% | -433.88% | -283.01% | -861.04% | -164.63% | -223.93% | -293.73% | -134.48% | 0.00% | -478.57% | -633.33% | -580.00% | -57.63% | -1,125.00% | 0.00% |
| Income Tax Expense | 0.00 | 631.00K | 1.66M | 1.06M | 1.46M | 4.33M | 1.12M | 1.96M | 263.00K | 496.00K | 45.00K | 0.00 | 80.00K | 1.23M | 223.00K | 1.89M | -578.00K | 509.00K | 177.00K | -170.00K | -3.86M | 418.00K | -269.00K | -355.00K | -100.00K | -900.00K | -200.00K | 200.00K | 100.00K | -270.00K | 0.00 |
| Net Income | -3.49M | -4.97M | -3.73M | -1.34M | -3.38M | 1.02M | -10.70M | -3.97M | -6.90M | -9.88M | -7.22M | -4.35M | -6.64M | -2.85M | -6.21M | -4.81M | 3.02M | -4.95M | -2.07M | -9.24M | -2.61M | -8.51M | -6.97M | -6.35M | -6.60M | -6.60M | -5.70M | -3.20M | -680.00K | -1.35M | -1.22M |
| Net Income Ratio | -3,560.20% | -38,246.15% | -4,601.23% | -1,308.82% | -9,391.67% | 1,782.46% | -4,383.61% | -656.20% | -1,138.94% | -1,200.85% | -611.96% | -127.65% | -184.71% | -84.60% | -400.77% | -365.22% | 290.84% | -506.45% | -210.58% | -861.04% | -164.63% | -223.93% | -283.40% | -127.76% | -200.00% | -471.43% | -633.33% | -640.00% | -57.63% | -1,125.00% | 0.00% |
| EPS | -0.07 | -0.15 | -0.28 | -0.12 | -1.02 | 0.02 | -1.01K | -4.75K | -2.30M | -4.94M | -7.22M | -4.35M | -6.64M | -2.85M | -24.85K | -19.24K | 12.06K | -0.36 | -0.15 | -0.68 | -0.19 | -0.62 | -0.51 | -0.47 | -0.48 | -0.48 | -0.42 | -1.60M | -0.05 | -0.10 | -0.09 |
| EPS Diluted | -0.07 | -0.15 | -0.28 | -0.12 | -1.02 | 0.02 | -972.36 | -4.75K | -2.30M | -4.94M | -7.22M | -4.35M | -6.64M | -2.85M | -24.85K | -19.24K | 12.06K | -0.36 | -0.15 | -0.68 | -0.19 | -0.62 | -0.51 | -0.47 | -0.48 | -0.48 | -0.42 | -1.60M | -0.05 | -0.10 | -0.09 |
| Weighted Avg Shares Out | 51.13M | 32.51M | 13.38M | 10.77M | 3.30M | 65.22M | 10.60K | 836.00 | 3.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 250.00 | 250.00 | 250.00 | 13.63M | 13.63M | 13.63M | 13.63M | 13.63M | 13.63M | 13.63M | 13.63M | 13.63M | 13.63M | 2.00 | 13.63M | 13.63M | 13.63M |
| Weighted Avg Shares Out (Dil) | 51.13M | 32.51M | 13.38M | 10.77M | 3.30M | 65.23M | 11.00K | 836.00 | 3.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 250.00 | 250.00 | 250.00 | 13.63M | 13.63M | 13.63M | 13.63M | 13.63M | 13.63M | 13.63M | 13.63M | 13.63M | 13.63M | 2.00 | 13.63M | 13.63M | 13.63M |
Guided Therapeutics Schedules Conference Call to Discuss Third Quarter 2015 Financial Results
NORCROSS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that it will report its 2015 third quarter financial results following the market close on Thursday,...
Guided Therapeutics Schedules Conference Call to Discuss Second Quarter 2015 Financial Results
NORCROSS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that it will report its 2015 second quarter financial results following the market close on Wednesday,...
FDA Completes Review of Guided Therapeutics’ LuViva® Advanced Cervical Scan PMA Application
NORCROSS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that it has received notification from the U.S. Food and Drug Administration (FDA) regarding the pre-market approval (PMA) application for the LuViva® Advanced Cervical Scan. In its most recent...
Guided Therapeutics to Report First Quarter 2015 Results and Hold Conference Call; Provide Update on LuViva FDA Timing
NORCROSS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), developer of a point-of-care and painless testing platform that uses biophotonics for the early detection of disease that leads to cervical cancer, today announced that it is scheduled to report financial...
Guided Therapeutics to Report Fourth Quarter 2014 Results and Hold Conference Call; Provide Update on Business Activity
NORCROSS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it is scheduled to report financial results for its fourth quarter...
Guided Therapeutics to Report Third Quarter 2014 Results and Hold Conference Call
NORCROSS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTCQB: GTHP), developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it is scheduled to report financial results for its third quarter ended September...
Guided Therapeutics to Report Second Quarter 2014 Results and Hold Conference Call
NORCROSS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it is scheduled to report financial results for its second quarter...
Guided Therapeutics to Report First Quarter 2014 Results and Hold Conference Call
NORCROSS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTCQB: GTHP), developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it is scheduled to report financial results for its first quarter ended March...
Guided Therapeutics to Report Fourth Quarter 2013 Results and Hold Conference Call
NORCROSS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it is scheduled to report financial results for its fourth quarter...
Source: https://incomestatements.info
Category: Stock Reports